The Clamp-Like Index
Open Access
- 1 September 2007
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 30 (9) , 2374-2380
Abstract
OBJECTIVE—Insulin resistance, the underlying pathophysiological mechanism of the metabolic syndrome, can not only predict type 2 diabetes development but also cardiovascular disease. Thus, precise insulin resistance measurement in individuals at risk for metabolic diseases would support clinical risk stratification. However, the gold standard for measuring insulin resistance, the hyperinsulinemic clamp test, is too labor intensive to be performed in large clinical studies/settings. RESEARCH DESIGN AND METHODS—Using plasma glucose and C-peptide concentrations from oral glucose tolerance tests (OGTTs), we developed the novel “clamp-like index” (CLIX) for insulin sensitivity calculation and compared CLIX to clamp glucose infusion rates (GIR) (100–120 min). We evaluated CLIX in 89 nondiabetic subjects (58 female and 31 male, aged 45 ± 1 years, BMI 27.5 ± 0.8 kg/m2) who underwent frequently sampled 3-h 75-g OGTTs and 2-h hyperinsulinemic-isoglycemic clamp (40 mU/min per m2) tests. RESULTS—CLIX, calculated as serum creatinine (×0.85 if male)/(mean AUCglucose × mean AUCC-peptide) × 6,600, was highly correlated (r = 0.670, P < 10−12) with and comparable to clamp GIRs100–120 min. In subgroup analyses, GIRs100–120 min were lower (P < 0.005) in type 2 diabetic offspring (6.2 ± 0.7 mg · min−1 · kg−1) than in sex-, age-, and BMI-matched subjects without a family history of type 2 diabetes (8.6 ± 0.5 mg · min−1 · kg−1), which was also reflected by CLIX (insulin-resistant offspring 6.4 ± 0.6 vs. those without a family history of type 2 diabetes 9.0 ± 0.5; P < 0.002). When compared with normal-weight subjects (GIR 8.8 ± 0.4 mg · min−1 · kg−1; CLIX 9.0 ± 0.5), both GIRs100–120 min and CLIX of obese (5.2 ± 0.9 mg · min −1 · kg−1; 5.7 ± 0.9) and morbidly obese (2.4 ± 0.4 mg · min −1 · kg−1; 3.3 ± 0.5) humans were lower (each P < 0.02). CONCLUSIONS—CLIX, a novel index obtained from plasma OGTT glucose and C-peptide levels and serum creatinine, without inclusion of anthropometrical measures to calculate insulin sensitivity in nondiabetic humans, highly correlates with clamp GIRs and reveals even slight insulin sensitivity alterations over a broad BMI range and is as sensitive as the hyperinsulinemic clamp test.Keywords
This publication has 35 references indexed in Scilit:
- Increased Plasma Amylin in Type 1 Diabetic Patients After Kidney and Pancreas TransplantationDiabetes Care, 2006
- Is insulin resistance the cause of the metabolic syndrome?Annals of Medicine, 2006
- Endothelial function, insulin action and cardiovascular risk factors in young healthy adult offspring of parents with Type 2 diabetes: effect of vitamin E in a randomized double‐blind, controlled clinical trialDiabetic Medicine, 2005
- Methods for clinical assessment of insulin sensitivity and β-cell functionBest Practice & Research Clinical Endocrinology & Metabolism, 2003
- Free Fatty Acids Inhibit the Glucose-Stimulated Increase of Intramuscular Glucose-6-Phosphate Concentration in HumansThe Journal of Clinical Endocrinology & Metabolism, 2001
- The euglycemic hyperinsulinemic clamp examination: variability and reproducibilityScandinavian Journal of Clinical and Laboratory Investigation, 2000
- Plasma levels of proinsulin, insulin and C-peptide in chronic renal, hepatic and muscular disorders.Japanese Journal of Medicine, 1984
- Kinetics of human connecting peptide in normal and diabetic subjects.Journal of Clinical Investigation, 1978
- Insulin Control of Glucose Metabolism in ManJournal of Clinical Investigation, 1975
- A Model of the Kinetics of Insulin in ManJournal of Clinical Investigation, 1974